daraxonrasib
36 articles
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
2026 AACR Annual Meeting Gives Hope for the Future
Research highlights from the 2026 AACR Meeting featured advances in pancreatic cancer treatment, focusing on KRAS and vaccines,
An Update on Drugs for KRAS Mutations
Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Rewinding 2025: A Year in Pancreatic Cancer Research
We take a look back at the research developments in 2025: KRAS, earlier detection and screening, vaccines, and clinical trials.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
The Latest Research from the 2025 AACR Special Conference
Highlights from the 2025 AACR Special Conference on pancreatic cancer research include updates on drugs that work on KRAS, AI and early detection, and biomarkers.
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
New Pain Control Technology for Locally Advanced Pancreatic Cancer
Dr. Hani Babiker outlines the results of the PANOVA-3 trial, which tested Tumor Treating Fields and chemotherapy for pain control.
Pancreatic Cancer Research Highlights from ASCO GI 2025
Read about the pancreatic cancer research highlights from the ASCO GI 2025 conference, where treatments and quality-of-life were discussed.
Tackling KRAS G12D
Dr. Leon Pappas explains the workings of the new KRAS G12D inhibitor, now in phase I/II clinical trials around the US and Australia.
Daraxonrasib: What To Know About Common Side Effects
Oncodermatologist Dr. Ian Tattersall discusses the rash caused by the new KRAS drug daraxonrasib, and best options to manage the rash.
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.